Amyloid binding ligands as Alzheimer's disease therapies (Q35019441)

5 August 2017

1 reference

title

Amyloid binding ligands as Alzheimer's disease therapies (English)

1 reference

5 August 2017

0 references

Virginia M-Y Lee

1

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

published in

Neurobiology of Aging

1 reference

5 August 2017

volume

23

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

1039-1042

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Transgenic mouse models of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Presenilin-1 mutations in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Beta-secretase revealed: starting gate for race to novel therapies for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Intracellular APP processing and A beta production in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900121-5

7 January 2021

10.1016/S0197-4580(02)00121-5

Identifiers

DOI

1 reference

5 August 2017

1 reference